Screener
LB Pharmaceuticals Inc LBRX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by LB Pharmaceuticals Inc in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: LB Pharmaceuticals Inc’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219607
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $7,119 | $2,127 |
| Accrued expenses | 3,057 | 4,585 |
| Operating lease liabilities, current | 730 | 730 |
| Total current liabilities | 10,906 | 7,442 |
| Derivative liability - warrants | 1,143 | 1,343 |
| Operating lease liabilities, noncurrent | 2,740 | 2,839 |
Item 1. Financial Statements
FAQ
- What is LB Pharmaceuticals Inc's accrued expenses?
- LB Pharmaceuticals Inc (LBRX) reported accrued expenses of $3.06M in Q1 2026.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about LB Pharmaceuticals Inc's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude